Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Imatinib-Resistant/Intolerant CML or Ph+ ALL
NCT00349518Phase 3Withdrawn
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2006
- Primary completion
- Jan 2007
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 6
01
Overview
A Phase 3 trial of dasatinib in chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), sponsored by Bristol Myers Squibb. Planned start Dec 2006; status: withdrawn.
02
Drugs
dasatinib
03
Conditions
chronic myeloid leukemia (CML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00349518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00349518.